(S032) Investigating CDKN2A Copy Number Loss in HPV- and HPV+ Head and Neck Cancer: A Demonstration of Integrated Genomic and Clinical Analyses Using TCGA
Chen W, Bindra R, Mo A, Hayman T, Husain Z, Contessa J, Yu J. (S032) Investigating CDKN2A Copy Number Loss in HPV- and HPV+ Head and Neck Cancer: A Demonstration of Integrated Genomic and Clinical Analyses Using TCGA. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e10. DOI: 10.1016/j.ijrobp.2017.02.068.Peer-Reviewed Original ResearchCDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis.
Chen W, Bindra R, Mo A, Hayman T, Husain Z, Contessa J, Gaffney S, Townsend J, Yu J. CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis. Journal Of Clinical Oncology 2017, 35: 6060-6060. DOI: 10.1200/jco.2017.35.15_suppl.6060.Peer-Reviewed Original ResearchCopy number lossNumber lossP16 protein expression levelsDisease-free survivalTumor suppressor proteinMedian disease-free survivalMedian overall survivalOverall survivalGene transcriptionSuppressor proteinCDKN2A mRNAProtein expression levelsGenomic groupsCopy number ratioCancer Genome Atlas (TCGA) headGenomic measurementsHPV statusPoor prognosisNeck cancerExpression levelsLoss groupTCGA analysisProtein expressionP16 protein expressionCDKN2A